Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican3derived peptide

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1019-1026

  Tada, Yoshitaka ^a,b   Yoshikawa, Toshiaki ^a   Shimomura, Manami ^a   Sawada, Yu ^a   Sakai, Mayuko ^a   Shirakawa, Hirofumi ^a   Nobuoka, Daisuke ^a   Nakatsura, Tetsuya ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

CTL clone; Glypican3; Peptide vaccine

Indexed keywords

GAMMA INTERFERON; GLYPICAN 3; HLA A1 ANTIGEN;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; GLYPICANS; HLA-A2 ANTIGEN; HUMANS; LIVER NEOPLASMS; MALE; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84882370749     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2044     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Zidan A, Scheuerlein H, Schüle S, Settmacher U and Rauchfuss F: Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon 12: e6894, 2012.
4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double blind, placebo controlled trial. Lancet Oncol 10: 25-34, 2009.
6. Kim HY and Park JW: Molecularly targeted therapies for hepatocellular carcinoma: Sorafenib as a stepping stone. Dig Dis 29: 303-309, 2011.
7. Morimoto M, Numata K, Kondo M, et al: Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 41: 296-302, 2011.
8. Greten TF, Manns MP and Korangy F: Immunotherapy of hepatocellular carcinoma. J Hepatol 45: 868-878, 2006.
9. Mizukoshi E, Nakamoto Y, Arai K, et al: Comparative analysis of various tumor associated antigen specific t cell responses in patients with hepatocellular carcinoma. Hepatology 53: 1206-1216, 2011.
10. Filmus J, Shi W, Wong ZM and Wong MJ: Identification of a new membrane bound heparan sulphate proteoglycan. Biochem J 311: 561-565, 1995.
11. Filmus J and Selleck SB: Glypicans: proteoglycans with a surprise. J Clin Invest 108: 497-501, 2001.
12. Nakatsura T, Yoshitake Y, Senju S, et al: Glypican 3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306: 16-25, 2003.
13. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E and Filmus J: Glypican 3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125: 89-97, 2003.
14. Nakatsura T and Nishimura Y: Usefulness of the novel oncofetal antigen glypican 3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19: 71-77, 2005.
15. Shirakawa H, Kuronuma T, Nishimura Y, et al: Glypican 3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 34: 649-656, 2009.
16. Shirakawa H, Suzuki H, Shimomura M, et al: Glypican 3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 100: 1403-1407, 2009.
17. Motomura Y, Senju S, Nakatsura T, et al: Embryonic stem cell derived dendritic cells expressing glypican 3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16 F10. Cancer Res 66: 2414-2422, 2006.
18. Motomura Y, Ikuta Y, Kuronuma T, et al: HLA A2 and A24 restricted glypican 3 derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 32: 985-990, 2008.
19. Iwama T, Horie K, Yoshikawa T, et al: Identification of an H2 Kb or H2 Db restricted and glypican 3 derived cytotoxic Tlymphocyte epitope peptide. Int J Oncol 42: 831-838, 2013.
20. Komori H, Nakatsura T, Senju S, et al: Identification of HLA A2 or HLA A24 restricted CTL epitopes possibly useful for glypican 3 specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2689-2697, 2006.
21. Nakatsura T, Komori H, Kubo T, et al: Mouse homologue of a novel human oncofetal antigen, glypican 3, evokes T cell mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 10: 8630-8640, 2004.
22. Imanish T, Akaza T, Kimura A, Tokunaga K and Gojobori T Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991. Vol 1. Tsuji K, Aizawa M and Sasazuki T (eds.) Oxford University Press, Oxford, pp1065-1220
23. Sidney J, Grey HM, Kubo RT and Sette A: Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17: 261-266, 1996.
24. Yasuda N, Tsuji K, Aizawa M, et al: HLA antigens in Japanese populations. Am J Hum Genet 28: 390-399, 1976.
25. Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ and Katovich Hurley C: Frequencies of HLA A2 alleles in five U.S. population groups. Predominance of A02011 and identification of HLA A0231. Hum Immunol 61: 334-340, 2000.
26. Mehra NK, Jaini R, Rajalingam R, Balamurugan A and Kaur G: Molecular diversity of HLAA02 in Asian Indians: predominance of A0211. Tissue Antigens 57: 502-507, 2001.
27. Sawada Y, Yoshikawa T, Nobuoka D, et al: Phase I trial of a glypican 3 derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 18: 3686-3696, 2012.
28. Yoshikawa T, Nakatsugawa M, Suzuki S, et al: HLA A2 restricted glypican 3 peptide specific CTL clones induced by peptide vaccine show high avidity and antigen specific killing activity against tumor cells. Cancer Sci 102: 918-925, 2011.
29. Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T and Nakatsura T: Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother 9: 210-212, 2013.
30. Sawada Y, Sakai M, Yoshikawa T, Ofuji K and Nakatsura T: A glypican 3 derived peptide vaccine against hepatocellular carcinoma. Oncoimmunology 1: 1448-1450, 2012.
31. Purbhoo MA, Li Y, Sutton DH, et al: The HLA A0201 restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high affinity T cell receptor. Mol Cancer Ther 6: 2081-2091, 2007.
32. Nakatsugawa M, Horie K, Yoshikawa T, et al: Identification of an HLAA0201 restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin. Int J Oncol 39: 1041-1049, 2011.
33. Guo Y, Zhu Y and Sun S: Identification and functional studies of HLA A0201 restricted CTL epitopes in the X protein of hepatitis B virus. Acta Virol 55: 107-115, 2011.
34. McKee MD, Roszkowski JJ and Nishimura MI: T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 3: 35, 2005.
35. Harada Y and Kawase I: Single cell based T cell receptor gene analysis reveals existence of expanded WT1 (Wilms' tumor gene) product specific T cell clones in leukemia patients but not healthy volunteers. Med J Osaka Univ 50: 1-12, 2007.
36. Tanaka Harada Y, Kawakami M, Oka Y, et al: Biased usage of BV gene families of T cell receptors of WT1 (Wilms' tumor gene) specific CD8+ T cells in patients with myeloid malignancies. Cancer Sci 101: 594-600, 2010.
37. Morimoto S, Oka Y, Tsuboi A, et al: Biased usage of T cell receptor chain variable region genes of Wilms' tumor gene (WT1) specific CD8+ T cells in patients with solid tumors and healthy donors. Cancer Sci 103: 408-414, 2012.
38. Valmori D, Dutoil V, Lienard D, et al: Tetramer guided analysis of TCR beta chain usage reveals a large repertoire of melan A specific CD8+ T cells in melanoma patients. J Immunol 165: 533-538, 2000.
39. Mandruzzato S, Rossi E, Bernardi F, et al: Large and dissimilar repertoire of Melan A/MART1 specific CTL in metastatic lesions and blood of a melanoma patient. J Immunol 169: 4017-4024, 2002.
40. Zhou J, Dudley ME, Rosenberg SA and Robbins PF: Selective growth, in vitro and in vivo, of individual T cell clones from tumor infiltrating lymphocytes obtained from patients with melanoma. J Immunol 173: 7622-7629, 2004.
41. Akiyama Y, Maruyama K, Tai S, et al: Characterization of a MAGE 1 derived HLA A24 epitope specific CTL line from a Japanese metastatic melanoma patient. Anticancer Res 29: 647-655, 2009.
42. Saper MA, Bjorkman PJ and Wiley DC: Refined structure of the human histocompatibility antigen HLAA2 at 2.6 A resolution. J Mol Biol 219: 277-319, 1991.
43. Madden DR, Garboczi DN and Wiley DC: The antigenic identity of peptide MHC complexes: a comparison of the conformations of five viral peptides presented by HLAA2. Cell 75: 693-708, 1993.
44. Sidney J, del Guercio MF, Southwood S, Hermanson G, Maewal A, Appella E and Sette A: The HLAA0207 peptide binding repertoire is limited to a subset of the A0201 repertoire. Hum Immunol 58: 12-20, 1997.
45. Rivoltini L, Loftus DJ, Barracchini K, et al: Binding and presentation of peptides derived from melanoma antigens MART1 and glycoprotein100 by HLAA2 subtypes: implications for peptide based immunotherapy. J Immunol 156: 3882-3891, 1996.
46. Sette A and Sidney J: HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10: 478-482, 1998.
47. Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, Saito N and Itoh K: Molecular basis of T cell mediated recognition of pancreatic cancer cells. Cancer Res 61: 2038-2046, 2001.
48. Nonaka Y, Tsuda N, Shichijo S, et al: Recognition of ADP?ribosylation factor 4?like by HLA?A2?restricted and tumor?reactive cytotoxic T lymphocytes from patients with brain tumors. Tissue Antigens 60: 319-327, 2002.
49. Sawada Y, Yoshikawa T, Fujii S, et al: Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican derived peptide vaccination: an autopsy case. Hum Vaccin Immunother 9: Mar 6, 2013 (Epub ahead of print).
50. Krausa P, Brywka M III, Savage D, et al: Genetic polymorphism within HLAA02: significant allelic variation revealed in different populations. Tissue Antigens 45: 223-231, 1995.
51. Chang CX, Tan AT, Or MY, et al: Conditional ligands for Asian HLA variants facilitate the definition of CD8(+) T cell responses in acute and chronic viral diseases. Eur J Immunol 43: 1109-1120, 2013.
52. Chen KY, Liu J and Ren EC: Structural and functional distinctiveness of HLAA2 allelic variants. Immunol Res 53: 182-190, 2012.
53. Shieh DC, Lin DT, Yang BS, Kuan HL and Kao KJ: High frequency of HLAA0207 subtype in Chinese population. Transfusion 36: 818-821, 1996.
54. Cheng LH, Jin SZ, Gao SQ, Li Z, Zou HY, Wang DM and Wu GG: Difference in HLAA 02 allele distribution between Han populations in south and north China. Di Yi Jun Yi Da Xue Xue Bao 25: 321-324, 2005 (In Chinese).
55. Mohana Devi S, Balachandar V, Arun M, Suresh Kumar S, Balamurali Krishnan B and Sasikala K: Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci 58: 759-767, 2013.